- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03264443
Hypertension Approaches in the Elderly: a Lifestyle Study (HAEL)
February 11, 2020 updated by: Hospital de Clinicas de Porto Alegre
Combined Training and Health Education for Hypertensive Elders: a Multicenter Randomized Clinical Trial
Two-center randomized, parallel, controlled trial which will compare a pragmatic combined training program with a health education program in 184 older adults with hypertension.
This study will last 12 weeks with assessments conducted at baseline, previously to the group allocation, and after interventions.
There is a set of secondary outcomes which show clinical importance to the elderly population and are possibly influenced by the tested intervention.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The present protocol describes a randomized controlled trial that aims to evaluate blood pressure effects of a pragmatic combined training program, with low equipment needs, in comparison with a health education program.
The sample is composed by 184 older adults, divided in two implementation centers.
Randomization ratio will be 1:1 and interventions will last 12 weeks, with three weekly sessions for the exercise arm and one to the health education arm.
In order to analyze the effects of interventions in a comprehensive way, a range of variables related to ambulatory blood pressure (primary outcome), physical fitness, vascular and autonomous function, together with emotional and cognitive aspects will be evaluated in a pre-post fashion.
The study's hypothesis, as well as the sample size calculation and analysis plan, is based on a superiority expectation for the exercise program in comparison with the health education program, especially for the blood pressure control, functional capacity and quality of life.
The present study was designed and will be conducted by a multidisciplinary staff and follows ethical and methodological recommendations for clinical trials.
It is expected that this multicenter randomized trial will provide scientific evidences with a high applicability to the non-pharmacological management of hypertension in the elderly.
Study Type
Interventional
Enrollment (Anticipated)
184
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Daniel Umpierre, PhD
- Phone Number: +555133596332
- Email: daniel.umpierre@gmail.com
Study Contact Backup
- Name: Lucas P Santos, MSc
- Phone Number: +555133596332
- Email: lucaspsantos87@gmail.com
Study Locations
-
-
Rio Grande Do Sul
-
Pelotas, Rio Grande Do Sul, Brazil
- Active, not recruiting
- Universidade Federal de Pelotas
-
Porto Alegre, Rio Grande Do Sul, Brazil
- Recruiting
- Hospital de Clínicas de Porto Alegre
-
Contact:
- Daniel Umpierre, PhD
- Phone Number: +555133596332
- Email: daniel.umpierre@gmail.com
-
Contact:
- Lucas P Santos, PhD
- Phone Number: Santos +555133596332
- Email: lucaspsantos87@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Hypertension diagnosis (through ambulatory blood pressure monitoring or medication use)
- Verified ability to exercise
- Unaltered pharmacological plan within previous 4 weeks
- Willingness to participate in any of interventions
Exclusion Criteria:
- Inability or refusal to give written consent
- Myocardial infarction, revascularization proceedings, deep vein thrombosis
- Severe cardiovascular disease (class III or IV heart failure, uncontrolled arrhythmia, unstable angina, or use of implantable defibrillator
- Chronic pulmonary disease which requires the use of oxygen or steroidal therapy
- Incidence of cardiovascular event, hospitalization or other severe health-related event during the experimental period
- High alcohol consumption (over 14 doses per week)
- Renal disease needing dialysis
- Language, cognitive or hearing problems
- Plans of moving to another city during the study
- Living together with another person enrolled in the study
- Osteoarticular or muscular injuries or another health conditions which generate inability to carry on the interventions
- Progressive neurological disorders (Parkinson, multiple sclerosis, etc.)
- Cancer treatment in the past 2 years
- A medical report indicating exercise counterindication based cardiopulmonary exercise testing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Health education
Patients will receive weekly lectures on hypertension related topics during 12 weeks.
|
Weekly group lectures (1h each) giving information on patient's best practices to manage hypertension.
|
Experimental: Combined training
Patients will complete 12 weeks of combined training (aerobic + strength exercise, 3x/week) in a pragmatic setup.
In order to make the interventions more similar, contents of the health education arm will also be discussed with patients receiving this intervention.
|
Combined training (aerobic and strength exercises), in moderate intensities (perceived exertion controlled) performed 3x/week (1h) duration with a education component (10') based on the contents of the health intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ambulatory Blood Pressure
Time Frame: Change from baseline 24-hour systolic blood pressure at 12 weeks
|
24h ambulatory blood pressure measured through automatic oscillometric device
|
Change from baseline 24-hour systolic blood pressure at 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Walking distance
Time Frame: Change from baseline walking distance at 12 weeks
|
Longest distance walked as assessed by the six-minute walk test
|
Change from baseline walking distance at 12 weeks
|
Lower limbs functional capacity
Time Frame: Change from baseline SPPB score at 12 weeks
|
By using the Short Physical Performance Battery (SPPB), lower-limb mobility will be assess in the following sequence: static standing balance, walking speed and indirect muscle strength
|
Change from baseline SPPB score at 12 weeks
|
Cardiorespiratory fitness
Time Frame: Change from baseline VO2peak at 12 weeks
|
Oxygen consumption at peak (VO2peak) as assessed by maximal cardiopulmonary exercise testing
|
Change from baseline VO2peak at 12 weeks
|
Geriatric Depression Symptoms
Time Frame: Change from baseline GDS-15 score at 12 weeks
|
15-item depression symptoms scale (GDS-15)
|
Change from baseline GDS-15 score at 12 weeks
|
Quality of life (QoL)
Time Frame: Change from baseline QoL score at 12 weeks
|
World Health Organization Quality of Life questionnaire
|
Change from baseline QoL score at 12 weeks
|
Autonomic function
Time Frame: Change from baseline beat-to-beat blood pressure variability at 12 weeks
|
Basal and during Stroop Color-Word Conflict Test beat-to-beat blood pressure variability
|
Change from baseline beat-to-beat blood pressure variability at 12 weeks
|
Endothelial function, early adaptation
Time Frame: Change from baseline FMD at 6 weeks
|
Flow-mediated dilatation (FMD) assessed through high resolution ultrasonography
|
Change from baseline FMD at 6 weeks
|
Endothelial function
Time Frame: Change from baseline FMD at 12 weeks
|
Flow-mediated dilatation (FMD) assessed through high resolution ultrasonography
|
Change from baseline FMD at 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Daniel Umpierre, PhD, Hospital de Clínicas de Porto Alegre
- Study Director: Stephanie S Pinto, PhD, Federal University of Pelotas
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Schaun GZ, Alberton CL, Gomes MLB, Santos LP, Bamman MM, Mendes GF, Hafele MS, Andrade LS, Alves L, DE Ataides VA, Carmona MA, Lazaro R, Botton CE, Umpierre D, Pinto SS, Wilhelm EN. Maximal Oxygen Uptake Is Underestimated during Incremental Testing in Hypertensive Older Adults: Findings from the HAEL Study. Med Sci Sports Exerc. 2021 Jul 1;53(7):1452-1459. doi: 10.1249/MSS.0000000000002598.
- Umpierre D, Santos LP, Botton CE, Wilhelm EN, Helal L, Schaun GZ, Ferreira GD, De Nardi AT, Pfeifer LO, da Silveira AD, Polanczyk CA, Mendes GF, Tanaka H, Alves L, Galliano L, Pescatello LS, Brizio ML, Bock PM, Campelo P, Moraes RS, Domingues MR, Schaan BD, Alberton CL, Pinto SS; The HAEL Study Group. The "Hypertension Approaches in the Elderly: a Lifestyle study" multicenter, randomized trial (HAEL Study): rationale and methodological protocol. BMC Public Health. 2019 May 29;19(1):657. doi: 10.1186/s12889-019-6970-3.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2017
Primary Completion (Anticipated)
August 1, 2020
Study Completion (Anticipated)
August 1, 2020
Study Registration Dates
First Submitted
August 22, 2017
First Submitted That Met QC Criteria
August 28, 2017
First Posted (Actual)
August 29, 2017
Study Record Updates
Last Update Posted (Actual)
February 12, 2020
Last Update Submitted That Met QC Criteria
February 11, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-0044 (Other Grant/Funding Number: FIPE/Hospital de Clínicas de Porto Alegre)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Individual participant data after will be shared after trial completion.
Data usage will be under the PI's auspices, but restrictions or screenings will not be imposed upon data requests.
ABPM data and any deemed relevant support information (sociodemographic, clinical history and allocated groups) will be shared if available.Details regarding the study's design and statistical plan can be obtained consulting the trial's protocol.
Data on other outcomes could be requested contacting the PI.
Data access will be available after all participants completed the study and will remain accessible for as long as deemed necessary by the study's committee.
Data sets, variables' dictionary and statistical analysis description will be made available online upon registration and acceptance of the study team's data sharing terms and policy.
IPD Sharing Time Frame
The individual participant dataset will become available at a public repository up to six months after the first study publication.
IPD Sharing Access Criteria
A simple registration will grant access to study datasets.
The website for these files is not defined at the time of registration.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BayerCompletedPrimary HypertensionChina
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Health education
-
Federal University of PelotasRecruiting
-
University of PretoriaUnknown
-
Universiti Sains MalaysiaNot yet recruitingKnowledge, Attitudes, Practice | Early Childhood Caries
-
Junyan ZhaoActive, not recruitingTumor Chemotherapy PatientsChina
-
Tianjin HospitalCompletedLumbar Disc HerniationChina
-
Federal University of PelotasRecruitingBreast Cancer FemaleBrazil
-
Taipei Medical UniversityActive, not recruiting
-
Chang Gung University of Science and TechnologyEnrolling by invitation
-
Saglik Bilimleri Universitesi Gulhane Tip FakultesiCompletedEarly Detection of CancerTurkey
-
University of WashingtonNational Institute on Aging (NIA)RecruitingOsteo Arthritis KneeUnited States